Cartography Biosciences

Building a smarter roadmap for precision therapeutics.

[Tech Week @Techweek_]

"Building a platform is one thing — translating it into the clinic is another." Sitting in on a candid #BOSTechWeek biotech convo right now with @FenwickWest’s Heidi Erlacher, @CartographyBio CEO Kevin Parker + @a16z's Jorge Conde @JorgeCondeBio

[Cartography Biosciences @CartographyBio]

Excited for #BIO2026. Since last year's conference, CBI-1214 entered the clinic, we've announced new strategic collaborations, and secured financing to advance next-generation tumor-selective cancer therapies. We're looking forward to connecting with investors and partners.

[Cartography Biosciences @CartographyBio]

#ASCO26: Sat 5/30, 9 AM–12 PM CDT, Poster 442a.

We're presenting the Phase 1, first-in-human study design for CBI-1214, our LY6G6D-targeted T-cell engager, in advanced/metastatic MSS/MSI-L colorectal cancer, a population with deep unmet need.

[Cartography Biosciences @CartographyBio]

CEO Kevin Parker takes the stage on Wed, May 27 at #AETEurope to share how single-cell genomics is helping us find the antigen targets and target pairs behind the next generation of T-cell engagers.

[Cartography Biosciences @CartographyBio]

We’re pleased to share that we've received a strategic investment from @SamsungVentures to advance our oncology pipeline and proprietary drug discovery platform. Read more: https://t.co/mlWWTfCDe8

[Cartography Biosciences @CartographyBio]

@GileadSciences has exercised its first option to license an oncology target discovered via our ATLAS & SUMMIT platforms, marking a key milestone in the collaboration and our systematic approach to uncover tumor-selective targets.

Read more: https://t.co/cpEqk38aVT

[Cartography Biosciences @CartographyBio]

Looking ahead to #AACR2026, where we’ll present new preclinical data on CB02, a novel tumor-associated antigen in AML and solid tumors identified using our ATLAS platform.

[Cartography Biosciences @CartographyBio]

During #NationalColorectalCancerAwarenessMonth, we recognize the patients & families working to change the trajectory of colorectal cancer.

We’re advancing CBI-1214, targeting LY6G6D, in a Phase 1 trial for MSS/MSI-L CRC to help expand treatment options for patients. #EnoughCRC

[Cartography Biosciences @CartographyBio]

We’ve dosed the 1st patient in our Phase 1 trial of CBI-1214, targeting LY6G6D in MSS/MSI-L colorectal cancer. This milestone marks our clinic entry with a selectively engineered program advancing more precise options for hard-to-treat cancers. Read more: https://t.co/NstpITP0VD

[BiotechTV @BiotechTV]

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: How does biotech come from the lab bench? Kevin Parker, CEO of @CartographyBio, discusses how his PhD research spun out and advice for future biotech founders.

[BiotechTV @BiotechTV]

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Kevin Parker, CEO of @CartographyBio, shares where he sees the future of oncology research.

[Cartography Biosciences @CartographyBio]

In a recent @BiotechTV conversation with Chloe Kirk, CEO Kevin Parker was asked when Cartography truly felt like it had hit its "aha" moment. His answer reflects a defining inflection point and the momentum that continues to carry us into the year ahead.

Listen in below.

[BiotechTV @BiotechTV]

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: BiotechTV sat down with @CartographyBio CEO Kevin Parker during JPM week to learn more about his entrepreneurial journey, the company, and its work to solve problems in cancer.

[Cartography Biosciences @CartographyBio]

#ICYMI CEO Kevin Parker spoke with @ky_lahucik at @Endpts about the Pfizer deal announced earlier this week, including why Cartography’s platform continues to resonate with large pharma. Read more below.
https://t.co/jlcls8xLJQ

[Cartography Biosciences @CartographyBio]

Read more: https://t.co/gQTFsxfWdq

[Cartography Biosciences @CartographyBio]

We announced a strategic collaboration with @Pfizer with over $850M in potential value, reinforcing the strength & scalability of our ATLAS and SUMMIT platforms. The partnership supports near term execution & long term value creation, with CBI 1214 remaining wholly owned.

[Cartography Biosciences @CartographyBio]

Wrapping up 2025, we’re grateful for meaningful progress at Cartography, including IND approval for CBI-1214, a step toward delivering more precise, tumor-targeted therapies to patients in need. Thank you to our team & partners for advancing our mission, & Happy New Year!

[Cartography Biosciences @CartographyBio]

We've received FDA IND approval & Fast Track designation for CBI-1214, our lead T-cell engager for colorectal #cancer. These milestones support advancement into Phase 1 & address a significant unmet need in CRC.

Read more: https://t.co/lD1mGJUHpY

[Cartography Biosciences @CartographyBio]

#JPM26 is only one month away! We continue to advance our platform to uncover novel, tumor-selective targets & look forward to sharing more on our lead program, CBI-1214, which is progressing toward the clinic for patients with colorectal #cancer.

[Cartography Biosciences @CartographyBio]

Five years ago, Cartography set out to accelerate #drugdiscovery through comprehensive antigen profiling & redefine how we target #cancer. We recently celebrated that milestone in Yosemite & now look ahead to bringing our first program, CBI-1214, into the clinic. Cheers, team!

[Cartography Biosciences @CartographyBio]

#ICYMI CEO Kevin Parker spoke with @d_samorodnitsky at @biospace about how we're pushing single-cell sequencing to new limits, uncovering targets others can't see. Read the feature below. https://t.co/lDj8VxuBWA